Evidence map›Paper›PMID 40146407›Full record

ArticleJournal of gastrointestinal cancer2025

A Novel Diagnostic Model of Biomarkers in the Washing Fluid Obtained by EUS-FNA in Pancreatic Cancer.

Chen-Fan Li, Lan-Xiang Hao, Yi-Jia Chen, En-De Lin, Chun-Ping Zhang, Li-Hua Wu, Xu-Ying Liao, Jia-Li Zhou, Jian-Hui Zhu, Ling-Hui Zhan and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Chen-Fan Li *Department of Medical Oncology, Fudan University Shanghai Cancer Center Xiamen Hospital, Xiamen, 361020, China.
Lan-Xiang Hao *Department of Pathology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361102, China.
Yi-Jia Chen *Department of Gastroenterology, the National Key Clinical Specialty, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361004, Fujian Provincev, P.R. China.
En-De Lin *Department of General Surgery, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361102, China.
Chun-Ping Zhang *Department of Gastroenterology, the National Key Clinical Specialty, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361004, Fujian Provincev, P.R. China.
Li-Hua WuThe Third Clinical Medical College, Fujian Medical University, Fuzhou, 350004, China.
Xu-Ying LiaoThe Third Clinical Medical College, Fujian Medical University, Fuzhou, 350004, China.
Jia-Li ZhouDepartment of Gastroenterology, the National Key Clinical Specialty, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361004, Fujian Provincev, P.R. China.
Jian-Hui ZhuCentre of Clinical Laboratory, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361102, China. zhujianhui@xmu.edu.cn.
Ling-Hui ZhanDepartment of Critical Care Medicine, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361102, China. oriental_power00@163.com.
Xian-Ming LiangCentre of Clinical Laboratory, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361102, China. 178292958@qq.com.
Yi-Qun HuDepartment of Gastroenterology, the National Key Clinical Specialty, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361004, Fujian Provincev, P.R. China. hyq0826@xmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsCurrently, there are no biomarkers with high accuracy in the detection of pancreatic cancer. This article aims to evaluate the performance of a novel diagnostic model based on a combination of biomarkers in the washing fluid obtained by EUS-FNA with imaging examination in pancreatic cancer.

methodsThis study included 59 patients with pancreatic lesions who underwent EUS-FNA and were categorized into malignant and benign groups on the basis of pathology diagnosis. The levels of CEA, CA19-9, CA125, CA724, CYFRA 21-1, IMP3, SMAD4, and S100P in EUS-FNA washing fluid were detected by ELISA. We attempted to construct a new diagnostic method by combining the above biomarkers with EUS, CT, MRI, and PET-CT.

resultsCEA, CA19-9, CA724, CA125, and CYFRA 21-1 showed statistical significance in the diagnosis of pancreatic cancer (AUC > 0.7, p < 0.05). CA724 had a specificity of up to 100% in the group with positive EUS diagnosis. If at least two positive imaging results (EUS/CT/MRI/PET-CT) combined with at least one tumor marker (CEA/CA199/CA724) in series, the sensitivity was 88.57% and the specificity was 91.67%.

conclusionsCombining the tumor markers CEA, CA19-9, CA724, CA125, and CYFRA 21-1 in the washing fluid of EUS-FNA with commonly used imaging methods can help distinguish benign and malignant pancreatic lesions.

Indexed as

Biomarkers, TumorEndoscopic Ultrasound-Guided Fine Needle AspirationPancreatic NeoplasmsAdultAgedAged, 80 and overAntigens, NeoplasmAntigens, Tumor-Associated, CarbohydrateCA-19-9 AntigenFemaleHumansKeratin-19MaleMiddle AgedPositron Emission Tomography Computed Tomographyantigen CYFRA21.1Antigens, NeoplasmAntigens, Tumor-Associated, CarbohydrateBiomarkers, TumorCA-19-9 AntigenCA-72-4 antigenKeratin-19DiagnosisEUS-FNAPancreatic cancerTumor markers

Identifiers

PMID40146407

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.